XTL Biopharmaceuticals Ltd ADR (XTLB) — Strategic Asset Allocation Index
XTL Biopharmaceuticals Ltd ADR (XTLB) has a Strategic Asset Allocation Index of 0.3% as of December 2024. Strategic assets (PP&E of $- plus long-term investments of $14.00K) total $14.00K, measured against net assets of $5.43 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is XTL Biopharmaceuticals Ltd ADR's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
XTL Biopharmaceuticals Ltd ADR Strategic Asset Allocation Index (2003–2024)
This chart shows how XTL Biopharmaceuticals Ltd ADR's Strategic Asset Allocation Index has evolved across 19 annual periods from 2003 to 2024. As of December 2024, the index stands at 0.3%, representing strategic assets of $14.00K against net assets of $5.43 Million USD. For live market cap and overall valuation, see XTLB market cap.
Annual Strategic Asset Allocation Index for XTL Biopharmaceuticals Ltd ADR (2003–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for XTL Biopharmaceuticals Ltd ADR from 2003 to 2024, covering 19 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See XTL Biopharmaceuticals Ltd ADR net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.3% | $14.00K | $- | $14.00K | $5.43 Million | ▲ +0.3 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $2.22 Million | ▼ 0.0 pp |
| 2021 | 0.0% | $1.00K | $1.00K | $- | $5.33 Million | ▼ 0.0 pp |
| 2020 | 0.0% | $2.00K | $2.00K | $- | $6.25 Million | ▲ +0.0 pp |
| 2019 | 0.0% | $2.00K | $2.00K | $- | $6.98 Million | ▼ -0.3 pp |
| 2016 | 0.4% | $10.00K | $10.00K | $- | $2.69 Million | ▲ +0.1 pp |
| 2015 | 0.2% | $11.00K | $11.00K | $- | $4.89 Million | ▼ -0.3 pp |
| 2014 | 0.5% | $24.00K | $24.00K | $- | $4.68 Million | ▼ -0.4 pp |
| 2013 | 0.9% | $61.00K | $61.00K | $- | $6.79 Million | ▲ +0.1 pp |
| 2012 | 0.8% | $72.00K | $72.00K | $- | $9.42 Million | ▼ -0.2 pp |
| 2011 | 0.9% | $32.00K | $32.00K | $- | $3.44 Million | ▼ -0.3 pp |
| 2010 | 1.2% | $35.00K | $35.00K | $- | $2.83 Million | ▼ -327.3 pp |
| 2009 | 328.6% | $23.00K | $23.00K | $- | $7.00K | ▲ +325.7 pp |
| 2008 | 2.9% | $41.00K | $41.00K | $- | $1.43 Million | ▲ +1.6 pp |
| 2007 | 1.2% | $106.00K | $106.00K | $- | $8.56 Million | ▼ -0.9 pp |
| 2006 | 2.2% | $490.00K | $490.00K | $- | $22.76 Million | ▼ -4.6 pp |
| 2005 | 6.8% | $762.00K | $762.00K | $- | $11.25 Million | ▲ +2.1 pp |
| 2004 | 4.6% | $908.00K | $908.00K | $- | $19.60 Million | ▼ -0.5 pp |
| 2003 | 5.1% | $1.05 Million | $1.05 Million | $- | $20.61 Million | — |